Epigenomics AG (Epigenomics AG) Total Current Assets : $4.50 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Epigenomics AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Epigenomics AG's total current assets for the quarter that ended in Jun. 2023 was $4.50 Mil.

Epigenomics AG Total Current Assets Historical Data

The historical data trend for Epigenomics AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Total Current Assets Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

20.79

13.47

6.65

26.79

11.46

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Current Assets	Get a 7-Day Free Trial															19.84	16.73	11.46	8.16	4.50

Epigenomics AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Epigenomics AG's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	10.631	+	0.095	+	0.065	+	0.666
	=	11.46

Epigenomics AG's Total Current Assets for the quarter that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.883	+	0.23	+	0	+	0.391
	=	4.50

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Epigenomics AG (OTCPK:EPGNY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Epigenomics AG's Liquidation Value for the quarter that ended in Jun. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.883	-	2.501	+	0.75 * 0.226	+	0.5 * 0
=	1.55

Epigenomics AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNY) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

EPGNF:USA ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020